GV and LabCorp will exit the oncology research software provider in an acquisition by Roche, which bought a 12.6% stake in 2016 at a $1.2bn valuation.
Pharmaceutical firm Roche agreed yesterday to acquire cancer research technology provider and portfolio company Flatiron Health, paying $1.9bn for the remainder of the company’s shares.
Roche already owns a 12.6% stake in Flatiron, meaning the acquisition will value the company at approximately $2.15bn.
Founded in 2012, Flatiron has developed electronic health record software configured for oncology research, as well as technology that can manage and develop cancer research data.
The company will continue to operate its current business models and…
